BioSpace News Archive

Shanghai Junshi Biosciences Co., Ltd announced a collaboration with Dr. Reddy’s Laboratories Limited to develop and commercialize toripalimab, the anti-PD-1 monoclonal antibody in Latin America, India, South Africa, and at the election of Dr. Reddy’s, also in Australia, New Zealand and other countries.

Renibus Therapeutics® presented positive final results from a Phase 2 trial evaluating RBT-1 in patients undergoing elective cardiac surgery during an oral presentation at the 103rd Annual American Association for Thoracic Surgery meeting at the Los Angeles Convention Center, taking place May 6-9, 2023 in Los Angeles, CA.

Independent biopharmaceutical company Specialised Therapeutics Asia is pleased to announce that a new therapy to treat rare gastrointestinal stromal tumours shown to improve survival has been approved for use in Singapore.

Bliss Biopharmaceutical Co., Ltd announced a clinical trial collaboration agreement with option for strategic collaboration with Eisai Co., Ltd., for BB-1701, eribulin-payload based ADC directed against Human Epidermal Growth Factor Receptor 2 for the treatment of cancers.

SomaLogic, Inc., a global leader in proteomics technology, announced that it is sponsoring the Genomax Research Grant Award for researchers in Singapore.

Innovent Biologics, Inc. announces that second interim analysis and survival analysis results of the ORIENT-31 study have been published in the Lancet Respiratory Medicine.

Innovent Biologics, Inc. announces that the first patient with Thyroid Eye Disease has been successfully dosed in the Phase 3 study of IBI311, a recombinant anti-insulin-like growth factor-1 receptor monoclonal antibody.

Telix Pharmaceuticals Limited announces that it has entered into an agreement with Bayer AG to supply Illuccix® [1] for the Phase III ARASTEP study.

Exelixis, Inc. announced that Lance Willsey, M.D. has informed the Board of Directors of his decision to resign from the Board, effective immediately.

Edwards Lifesciences announced new data from the COMMENCE aortic trial, demonstrating low rates of structural valve deterioration in bioprosthetic aortic valves with the company’s innovative RESILIA tissue.